Skip to main content

Table 1 Patients´ characteristics

From: Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study

Median Age (years, range) 74 (59–82)
Gleason Score n (%)  
Low risk (≤6) 5 (33.3)
Intermediate risk (7) 4 (26.7)
High risk (>7) 6 (40.0)
Serum PSA (ng/ml) n (%)  
Low risk (≤10) 7 (46.7)
Intermediate risk (10–20) 3 (20.0)
High risk (>20) 5 (33.3)
Initial tumor stage (clinical examination and CT/MRI), n (%)  
Biopsy T1c 7 (46.7)
Intermediate risk (T2b) 1 (6.7)
High risk (≥T2c) 7 (46.7)
  1. Gleason score, PSA levels and Tumor stage risk group assignment according to the 2014 National Comprehensive Cancer Network guidelines on prostate cancer